20:43 , Nov 10, 2017 |  BC Week In Review  |  Financial News

EIB backs development of AntibioTx anti-infective

AntibioTx A/S (Hellerup, Denmark) is to receive €20 million ($23.2 million) from a tranched financing with the European Investment Bank to support Phase II and Phase III development of lead candidate ATx201 to treat skin...
22:11 , Nov 3, 2017 |  BC Extra  |  Financial News

EIB backs development of AntibioTx anti-infective

AntibioTx A/S (Hellerup, Denmark) will receive €20 million ($23.2 million) from a tranched financing with the European Investment Bank to support Phase II and Phase III development of lead candidate ATx201 to treat skin infections. Co-founder...